Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

33.10 +0.74 (+2.30%)
Streaming Delayed Price Updated: 1:47 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 Next >
Collegium Announces $150 Million Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $25 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
From Avalo Therapeutics
Via GlobeNewswire
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Appoints Nancy S. Lurker to its Board of Directors
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Provides 2025 Financial Guidance and Business Update
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Record Third Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Appoints Vikram Karnani as Chief Executive Officer
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Completes Acquisition of Ironshore Therapeutics
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Reports Second Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Jefferies Global Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $35 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.